Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

454

Participants

Timeline

Start Date

September 7, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2029

Conditions
Nasopharyngeal Carcinoma
Interventions
RADIATION

IMRT and concurrent cisplatin

Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated radiotherapy (IMRT)

DRUG

gemcitabine and cisplatin (Induction chemotherapy)

Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy

Trial Locations (8)

528499

NOT_YET_RECRUITING

Zhongshan City People's Hospital, Zhongshan

530021

NOT_YET_RECRUITING

The First Affiliated Hospital of Guangxi Medical University, Nanning

Unknown

NOT_YET_RECRUITING

Guangzhou Panyu Central Hospital, Guangzhou

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

NOT_YET_RECRUITING

Cancer Hospital of Guizhou Province, Guiyang

NOT_YET_RECRUITING

Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology, Wuhan

NOT_YET_RECRUITING

Union Hospital, Tongji Medical College,Huazhong University of Science and Technology;, Wuhan

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

collaborator

Zhongshan People's Hospital, Guangdong, China

OTHER

collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

collaborator

Tongji Hospital

OTHER

collaborator

Guangzhou Panyu Central Hospital

OTHER

collaborator

Hunan Cancer Hospital

OTHER

collaborator

Cancer Hospital of Guizhou Province

OTHER

lead

Sun Yat-sen University

OTHER